Ibuprofen (Brufen) - Dose, Uses, Side effects, Brands

Ibuprofen (Brufen) is a non-opioid, non-steroidal anti-inflammatory medicine that has antipyretic, analgesic, and anti-inflammatory properties.


It is used to treat the following conditions:

  1. Inflammatory and autoimmune rheumatic disorders
  2. Mild to moderate pain
  3. As an antipyretic (for fever)
  4. Osteoarthritis
  5. Dysmenorrhea
  6. Acute flares of gout
  7. Pericarditis

OTC (Over the counter) indications include:

  1. Fever
  2. Pain due to:
    1. Headache
    2. Migraine
    3. Sore throat
    4. Arthritis
    5. Sprains
    6. Menstrual pain
    7. Dental pain
    8. Minor muscles and joint pain
    9. Backache, and
    10. Cold and flu

[bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Dose in Adults" collapse_text="Dose in Adults" ]

Ibuprofen for mild to moderate pain:

  • Oral tablets: 200 mg to 800 mg twice or thrice daily (the usual daily dose is 1200 to 2400 mg per day

(Maximum daily dose is 3200 mg per day)

  • According to the manufacturers labeling, the usual dose is 400 mg every 4 to 6 hours as needed to a maximum dose of 3200 mg per day.
  • According to the American pain society:
    • 200 to 400 mg every 4 to 6 hours to a maximum dose of 3200 mg per day.

Ibuprofen for fever:

  • Intravenous ibuprofen initially 400 mg then 200 mg every 4 to 6 hours as needed

Ibuprofen for dysmenorrhea:

  • 200 to 800 mg three to four times daily (usual dose is 1200 to 2400 mg/day for a maximum of 3 to 5 days.
  • The manufacturers advise 400 mg every 4 hours as needed (maximum 3200 mg daily)

Ibuprofen for Acute flares of gout:

  • 800 mg three times daily for 5 to 7 days.
  • It should be started within 24 to 48 hours of symptoms onset and continued for 3 to 4 days after the resolution of symptoms.

Ibuprofen dose in patients with osteoarthritis:

  • 400 to 800 mg three or four times daily (maximum: 3200 mg per day)

Ibuprofen dose in patients with Rheumatoid arthritis:

  • 400 to 800 mg three or four times a day (maximum 3200 mg daily)

Ibuprofen dose in patients with Pericarditis:

Acute pericarditis:

  • 600 mg every 8 hours for 7 to 14 days followed by a gradual tapering of the dose by 200 to 400 mg at every one to two weeks interval.

Recurrent Pericarditis:

  • 600 mg every 8 hours (range 1200 to 2400 mg) for weeks to months until complete resolution of the symptoms followed by a gradual tapering of the dose by 200 mg per week.

Ibuprofen as OTC (over the counter labeling):

  • For analgesia and fever:

    • 200 mg every 4 to 6 hours as needed (may increase the dose to 400 mg every 4 to 6 hours) to a maximum of 1200 mg per day.
    • It should not be continued for more than 3 days for fever and for more than 10 days for pain
  • For migraine:

    • 400 mg at the onset of symptoms (maximum 400 mg per 24 hours)

[/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Dose in Children" collapse_text="Dose in children" ]

Ibuprofen dosage for pain relief:

  • Infants and children less than 50 kgs (should not be used in children less than 6 months):
    • 4 to 10 mg/kg/dose orally every 6 to 8 hours

Maximum single oral dose: 400 mg

Maximum daily oral dose: 40 mg/kg/day

  • Infants more than 6 months and less than 12 years of age:

    • 10 mg/kg intravenously every 4 to 6 hours as needed (the maximum daily dose is 40 mg/kg/day or 2400 mg per day whichever is less.
  • Children and adolescents 12 to 17 years:

    • 400 mg every 4 to 6 hours as needed to a maximum of 2400 mg per day.

Ibuprofen dose in fever:

  • Infants >6 months of age, children, and adolescents:
    • 5 to 10 mg/ kg/dose orally every 6 to 8 hours

A maximum single dose is 400 mg

Maximum daily dose: 40 mg/kg/day or 1200 mg/day unless directed by a physician (may use up to 2400 mg per day).

Intravenous Ibuprofen dose:

  • Infants more than 6 months and less than 12 years of age:

    • 10 mg/kg intravenously

Maximum single intravenous dose: 400 mg every 4 to 6 hours as needed.

Maximum daily intravenous dose 40 mg/kg/day or 2400 mg/day whichever is less

  • Children and adolescents 12 to 17:

    • 400 mg intravenously every 4 to 6 hours as needed

The maximum daily dose is 2400 mg per day


Ibuprofen dose in Juvenile idiopathic arthritis:

Oral dose in children:

  • 30 to 40 mg/kg/day in 3 or 4 divided doses.
  • Mild diseases may be treated with 20 mg/kg/day, severe diseases may be treated with 50 mg/kg/day.

The maximum single daily dose is 800 mg per day.

The maximum daily dose is 2400 mg//day.


Ibuprofen dose in Patent ductus arteriosus:

Intravenous ibuprofen dose:

  • Infants weighing between 0.5 Kg to 1.5 kgs and less than 32 weeks of gestation:
    • Initial dose of 10 mg/kg followed by two doses of 5 mg /kg at 24 and 48 hours of the initial dose

Ibuprofen OTC dosing for fever and pain:

Ibuprofen Dosing (Infants and Children 6 months to 11 years)

Weight in Kgs Weight in Pounds Age  dosage in mg
5.4 to 8.1 12 to 17 6 to 11 mo 50
8.2 to 10.8 18 to 23 12 to 23 mo 75
10.9 to 16.3 24 to 35 2 to 3 y 100
16.4 to 21.7 36 to 47 4 to 5 y 150
21.8 to 27.2 48 to 59 6 to 8 y 200
27.3 to 32.6 60 to 71 9 to 10 y 250
32.7 to 43.2 72 to 95 11 y 300

  [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Contraindications & Warnings" collapse_text="Contraindications & warnings" ]

Alert!: US Boxed Warning

  • It is contraindicated in cardiac bypass graft surgery.
  • Non-steroidal anti-inflammatory drugs and so Ibuprofen has been associated with an increased risk of stroke and myocardial infarction.
  • The risks increase when it is taken for a longer duration.
  • NSAIDs increase the risk of serious gastrointestinal perforations, bleeding, and ulcerations.
  • Patients, especially at risk of getting gastrointestinal related complications to include older patients, those with a previous history of peptic ulcer disease, and patients taking other medicines that may cause gastric ulceration.

Contraindications to Ibuprofen:

 

  • Hypersensitivity or allergy to ibuprofen, or any of its components.
  • History of asthma, urticaria, or bronchial hyperreactivity to aspirin and other NSAIDs
  • Patients who had CABG performed
  • These conditions may affect neonates:
    • Pulmonary atresia
    • Coarctation of the aorta
    • Tetralogy of Fallot
  • Patients with severe thrombocytopenia and intracranial bleeding are at greater risk.
  • Necrotizing enterocolitis
  • Grave renal insufficiency
  • Heart failure
  • Hepatic impairments ranging from mild to severe
  • Hyperkalemia
  • The third trimester is the most important.
  • During breastfeeding

Other warnings:

  • Ibuprofen can increase bleeding time due to defective platelet adhesion or aggregation. It can also be associated with severe blood disorders.
  • Hepatic impairment can occur. It is important to monitor LFTs
  • Hyperkalemia can be caused by Ibuprofen and other NSAIDs. Hyperkalemia is more marked in patients taking potassium-sparing diuretics like spironolactone and drugs affecting the Renin-angiotensin-aldosterone system like ACE inhibitors and ARBs.
  • It can cause nephrotoxicity. Patients who are dehydrated or taking other nephrotoxic medications can experience renal injury. Papillary necrosis may occur if ibuprofen is used long-term.
  • It may also cause serious skin reactions like steven-johnson syndrome and exfoliative dermatitis.
  • Aspirin-sensitive asthma patients are advised to avoid it
  • It can cause aseptic meningitis.

Ibuprofen: Drug Interaction

Risk Factor C (Monitor therapy)

5-Aminosalicylic Acid Derivatives

Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.)

May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.

Alcohol (Ethyl)

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.

Aliskiren

Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent. Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.

Aminoglycosides

Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.

Aminolevulinic Acid (Topical)

Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical).

Angiotensin II Receptor Blockers

May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.

Angiotensin-Converting Enzyme Inhibitors

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.

Anticoagulants

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin.

Anticoagulants

Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. Exceptions: Bemiparin; Enoxaparin; Heparin.

Beta-Blockers

Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. Exceptions: Levobunolol; Metipranolol.

Bisphosphonate Derivatives

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.

Cephalothin

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased.

Collagenase (Systemic)

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.

Corticosteroids (Systemic)

May enhance the adverse/toxic effect of Nonsteroidal AntiInflammatory Agents (Nonselective).

Dasatinib

May enhance the anticoagulant effect of Agents with Antiplatelet Properties. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.

Deferasirox

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.

Deoxycholic Acid

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.

Desmopressin

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.

Digoxin

Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.

Drospirenone

Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone.

Eplerenone

Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.

Fat Emulsion (Fish Oil Based)

May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.

Felbinac

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Glucosamine

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Haloperidol

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.

HydrALAZINE

Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.

Ibritumomab Tiuxetan

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding.

Ibrutinib

May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.

Inotersen

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Limaprost

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Lumacaftor

May decrease the serum concentration of Ibuprofen.

Multivitamins/Fluoride (with ADE)

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Multivitamins/Minerals (with ADEK, Folate, Iron)

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Multivitamins/Minerals (with AE, No Iron)

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Naftazone

May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.

Obinutuzumab

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.

Omega-3 Fatty Acids

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Pentosan Polysulfate Sodium

May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.

Pentoxifylline

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Porfimer

Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.

Potassium-Sparing Diuretics

Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.

PRALAtrexate

Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.

Probenecid

May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.

Prostacyclin Analogues

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Prostaglandins (Ophthalmic)

Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).

Quinolones

Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.

Salicylates

Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.

Serotonin/Norepinephrine Reuptake Inhibitors

May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).

Tacrolimus (Systemic)

Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic).

Thiazide and Thiazide-Like Diuretics

May enhance the nephrotoxic effect of Nonsteroidal AntiInflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.

Thrombolytic Agents

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.

Tipranavir

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Tolperisone

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents.

Tricyclic Antidepressants (Tertiary Amine)

May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).

Vancomycin

Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.

Verteporfin

Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin.

Vitamin E (Systemic)

May enhance the antiplatelet effect of Agents with Antiplatelet Properties.

Voriconazole

May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.

Risk Factor D (Consider therapy modification)

Apixaban

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.

Bemiparin

Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.

Bemiparin

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.

Bile Acid Sequestrants

May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.

CycloSPORINE (Systemic)

Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.

Dabigatran Etexilate

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.

Diclofenac (Systemic)

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs). Avoid the use of diclofenac/misoprostol with other NSAIDs.

Edoxaban

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.

Enoxaparin

Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue nonsteroidal anti-inflammatory agents (NSAIDs) prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.

Enoxaparin

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin. Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.

Heparin

Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required.

Heparin

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry)

May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. Management: Avoid combination when possible. If used, monitor more closely for evidence of bleeding. Discontinue herbal products with anticoagulant or antiplatelet actions 2 weeks prior to surgical, dental, or invasive procedures.

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry)

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.

Imatinib

Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib. Available evidence suggests other NSAIDs do not interact in a similar manner.

Lithium

Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.

Loop Diuretics

Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.

Methotrexate

Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.

PEMEtrexed

Ibuprofen may increase the serum concentration of PEMEtrexed. Management: In patients with an estimated creatinine clearance of 45 to 79 mL/min, avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed. Monitor for increased pemetrexed toxicities if combined.

Rivaroxaban

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.

Salicylates

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Exceptions: Choline Magnesium Trisalicylate.

Selective Serotonin Reuptake Inhibitors

May enhance the antiplatelet effect of Nonsteroidal AntiInflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.

Sincalide

Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.

Sodium Phosphates

May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.

Tenofovir Products

Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.

Vitamin K Antagonists (eg, warfarin)

Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.

Risk Factor X (Avoid combination)

Acemetacin

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Aminolevulinic Acid (Systemic)

Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic).

Dexibuprofen

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen.

Dexketoprofen

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Floctafenine

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Ketorolac (Nasal)

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Ketorolac (Systemic)

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Macimorelin

Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin.

Mifamurtide

Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide.

Morniflumate

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective)

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective).

Omacetaxine

Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.

Pelubiprofen

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Phenylbutazone

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Talniflumate

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Tenoxicam

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

Urokinase

Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase.

Zaltoprofen

May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.

 

Avoid in advanced renal disease.

According to the KDIGO 2012 guidelines:

  • Avoid use if eGFR is less than 30 ml/min
  • eGFR of 30 -60 ml/min: avoid use if there is a risk of worsening renal failure

[/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Dose in Liver disease" collapse_text="Dose in Liver disease" ]

Dose in liver disease:

No dose adjustment has been provided by the manufacturer in liver diseases. However, it should be used with caution in advanced liver disease. [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="How to Administer?" collapse_text="How to Administer?" ]

How to administer Ibuprofen?

Oral ibuprofen should best be taken with water or milk after meals. The intravenous formulation should be infused over at least 30 minutes. [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Pregnancy and lactation" collapse_text="Pregnancy and lactation" ]

Pregnancy Risk Factor C ( <30 weeks), D (> 30 weeks)

Some studies have shown that birth defects can be found. Data on teratogenicity are not consistent. Following pregnancy, ibuprofen exposure has been shown to have the following non-teratogenic effects:

        • Pre-birth constriction of the arteriosus ductus
        • The newborn may have persistent pulmonary hypertension.
        • Oligohydramnios,
        • Necrotizing enterocolitis,
        • Failure or dysfunction of the renal system
        • Intracranial hemorrhage

Ibuprofen is sometimes preferred to other NSAIDs during pregnancy for migraine treatment. However, there are other types of medicine that may be more effective than NSAIDs. Infertility has also been linked to NSAIDs, but this can be reversed by stopping taking the medication. Ibuprofen during breastfeeding: Ibuprofen is small enough to enter breastmilk in small amounts. No adverse effects have been reported in infants. Ibuprofen might be preferable to other NSAIDs in postpartum pain. When taken in the recommended dosages, Ibuprofen is considered compatible with breastfeeding by the WHO. [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Side effects" collapse_text="Side effects" ]

Common Side effects of ibuprofen:

Common side effects include an elevation in liver enzymes and anemia.

Less common side effects include:

    • dizziness, headache, and vertigo
    • edema, rash, and pruritis
    • Fluid retention
    • Gastric ulceration, heartburn, dyspepsia, gastrointestinal bleeding, nausea and vomiting, abdominal pain, cramps, constipation and bloating
    • prolonged bleeding time
    • Tinnitus and renal injury
  • Other less common side effects include:

    • Hypotension, syncope, and tachycardia
    • anxiety, malaise, and diaphoresis
    • ecchymosis, rectal bleeding, and stomatitis
    • dysuria, oliguria, and proteinuria
    • leukopenia, infections, and sepsis
    • asthenia, tremors, and interstitial nephritis

[/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Monitoring parameters" collapse_text="Monitoring parameters" ]

Monitor:

Patients should monitor Blood CBC, Chemistry, Renal functions, and liver functions. Patients should be monitored for weight gain, bleeding, bruising, and, gastrointestinal side effects. [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Pharmacology" collapse_text="Pharmacology" ]

Mechanism of action of Ibuprofen:

It reverses the inhibition of cyclooxygenase 1, 2 (COX 1), which results in decreased prostaglandin formation. It is antipyretic, analgesic and anti-inflammatory. Onset of action: 30 to 60 minutes (The maximum effect: 2 - 4 hours) The total duration of action is 6 - 8 hours. It is rapidly absorbed with a bioavailability of 80% and is 99% protein bound. Metabolism is via the liver Excretion is via urine (metabolites) Half-life elimination is about 0.5 to 1.5 hours.   [/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="International brands" collapse_text="International brands" ]

Ibuprofen Brand Names (International):

  • Actiprofen
  • Actron
  • Adagin
  • Adex 200
  • Adex Liqui-Gels
  • Advel
  • Advil
  • Afebril
  • Aktren
  • Algofen
  • Am-Fam 400
  • Anafen
  • Anco
  • Antarene
  • Arfen
  • Argifen
  • Asfen-400
  • Balkaprofen
  • Bebyzal
  • Bestafen
  • Bifen
  • Bofen
  • Brufen
  • Brufen 400
  • Brufen Forte
  • Brufen Retard
  • Brufen Syrup for Children
  • Brufort
  • Brupro
  • Bufect
  • Bufect Forte
  • Buplex
  • Buprex
  • Buprophar
  • Burana
  • Butafen
  • Carol
  • Cefen
  • Cuprofen
  • Dafen-Q
  • Dalsy
  • Degiton
  • Diffutab SR 600
  • Dolafen
  • Dolan FP
  • Dolex
  • Dolgit
  • Dolocyl
  • Dolomax
  • Doloral
  • Dolormin
  • Dolprin
  • Druisel
  • Easofen
  • Evofen
  • Expanfen
  • Extrapan Gel
  • Farsifen Forte
  • Febratic
  • Febryn
  • Fenatic
  • Fenbid
  • Fenpaed
  • Fever-Free
  • Flamex
  • Focus
  • Genofen
  • Gofen
  • Gyno-neuralgin
  • Hagifen
  • Ibufac
  • Ibufen
  • Ibuflam
  • Ibufug
  • Ibugesic
  • Ibugic
  • Ibulgan
  • Ibumetin
  • Ibunorm
  • Ibupirac
  • Ibuprofen
  • Ibusal
  • Ibuspan
  • Ibutop
  • Imet
  • Infacalm
  • Inufen
  • Ipren
  • Iprox
  • Ipufen
  • Irfen
  • Junifen
  • Liptan
  • Medicol
  • Medicol Advance
  • Mensoton
  • Mepabrufen
  • Mofen
  • Moris
  • Moris Forte
  • Motrin
  • Mutrim
  • Neoprofen
  • Neutropain
  • Nobafon
  • Noritis
  • Novogent
  • Nureflex
  • Nurofen
  • Nurofen for Children
  • Nurofen Gel
  • Nurofen Pro san sucre
  • Nuroffen
  • Nurosan
  • Optifen
  • Opturem
  • Ostarin
  • P-Fen
  • Panafen
  • Pedea
  • Peflam
  • Perfen
  • Perofen
  • Profen
  • Profinal
  • Proris
  • Prosinal
  • Provon
  • Quadrax
  • Rafen
  • Ranofen
  • RatioDolor
  • Remofen
  • Rhelafen
  • Rhelafen Forte
  • Rheumanox
  • Rupan
  • Ruprofen
  • Sapofen
  • Spedifen
  • Speedifen
  • Spifen
  • Syntofene
  • Tabalon
  • Tabalon 400
  • Tarein
  • Taskine
  • Tefin
  • Tenvalin
  • Thomaprodol
  • Ufen
  • Upfen
  • Uprofen
  • Urem
  • Vantril
  • Xfen Flashtab
  • Zofen
  • Zorafen

[/bg_collapse]   [bg_collapse view="button-blue" color="#f7f7f7" icon="arrow" expand_text="Brands in Pakistan" collapse_text="Brands in Pakistan" ]

Ibuprofen Brand Names in Pakistan

Ibuprofen Syrup 100 mg/5ml

Al-Fen Alina Combine Pharmaceuticals (Pvt) Ltd.
Hebofen Heal Pharmaceuticals Pvt Ltd
Micafen Max Pharmaceuticals

 

Ibuprofen Susp 100 mg/5ml

Actifen Glaxosmithkline
Aksofen Akson Pharmaceuticals (Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Amofen Ameer Pharma
Artijesic Medisearch Pharmacal(Pvt) Ltd
Artijesic Medisearch Pharmacal(Pvt) Ltd
Azofin Alkemy Pharmaceutical Laboratories (Private) Ltd.
Azofin Alkemy Pharmaceutical Laboratories (Private) Ltd.
Befen Rakaposhi Pharmaceutical (Pvt) Ltd.
Bepofen Lotus Pharmaceuticals (Pvt) Ltd
Bepofen Lotus Pharmaceuticals (Pvt) Ltd
Bepofen Lotus Pharmaceuticals (Pvt) Ltd
Biofen Bio Labs (Pvt) Ltd.
Bludol Standpharm Pakistan (Pvt) Ltd.
Blufen Bloom Pharmaceuticals (Pvt) Ltd.
Brosun Hisun Pharmaceuticals
Brufed Fedro Pharmaceutical
Brufedin Ardin Pharmaceuticals
Brufedin Ardin Pharmaceuticals
Brufen Abbott Laboratories (Pakistan) Limited.
Brufen Abbott Laboratories (Pakistan) Limited.
Brugesic Umersons
Deltafen Delta Pharma (Pvt) Ltd.
Dolocol Semos Pharmaceuticals (Pvt) Ltd.
Dorafen Dosaco Laboratories
Eprofen Epoch Pharmaceutical
Eprofen Epoch Pharmaceutical
Everfen Evergreen Pharmaceuticals Pvt Limited
Exifin Genix Pharma (Pvt) Ltd
Fenbro Stanley Pharmaceuticals (Pvt) Ltd.
Fenober Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Fenober Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Fenober Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Flumax Max Pharmaceuticals
Fynkoben Fynk Pharmaceuticals
Glare Sus Shrooq Pharmaceuticals
Hibtol Don Valley Pharmaceuticals (Pvt) Ltd.
Hugon Hizat Pharmaceutical Industries (Pvt) Ltd.
Ibofen Nova Med Pharmaceuticals
Ibofen Nova Med Pharmaceuticals
Ibofen Nova Med Pharmaceuticals
Iboz Z-Jans Pharmaceutical (Pvt) Ltd.
Ibu-Gesic Polyfine Chempharma (Pvt) Ltd.
Ibu-U Universal Pharmaceuticals (Pvt) Ltd
Ibucil Mediceena Pharma (Pvt) Ltd.
Ibugen Genera Pharmaceuticals
Ibugesic Wilsons Pharmaceuticals
Ibulexin Lexicon Pharmaceuticals (Pvt) Ltd.
Ibuped Alliance Pharmaceuticals (Pvt) Ltd.
Ibuprofen Lisko Pakistan (Pvt) Ltd
Ibuprofen British Pharmaceuticals Ltd
Ibuprofen Lisko Pakistan (Pvt) Ltd
Ibuprofen Lisko Pakistan (Pvt) Ltd
Ibuprofen Munawar Pharma (Pvt) Ltd.
Ibuprofen Munawar Pharma (Pvt) Ltd.
Ibupros Paramount Pharmaceuticals
Ibupros Paramount Pharmaceuticals
Ibupros Paramount Pharmaceuticals
Iburfen Mediate Pharmaceuticals (Pvt) Ltd
Iburin Hamaz Pharmaceutical (Pvt) Ltd.
Ibuser Star Laboratories (Pvt) Ltd.
Ibuser Star Laboratories (Pvt) Ltd.
Ibusim Simz Pharmaceuticals
Imcofen Imco Pharmaceuticals Laboratories
Inflam Spencer Pharma
Inflam Spencer Pharma
Inzel Raazee Theraputics (Pvt) Ltd.
Iodofen Ideal Pharmaceutical Industries
Isen Ici Pakistan Ltd.
Jaefen Irza Pharma (Pvt) Ltd.
Jaefen Irza Pharma (Pvt) Ltd.
Lemach Leama Chemi Pharma (Pvt.) Ltd.
Mb-Fen Multinational Buisness Link
Medfen Medicraft Pharmaceuticals (Pvt) Ltd.
Medibrufen Mediate Pharmaceuticals (Pvt) Ltd
Medibrufen Mediate Pharmaceuticals (Pvt) Ltd
Megafen Albro Pharma
Mufen Macquins International
Nenfen Nenza Pharmaceuticals (Pvt) Limited
Neoprofen Neo Medix
Neuprofen Neutro Pharma (Pvt) Ltd.
Novofen Krka-Pak Pharmaceutical & Chemical Works
Ocefen Safe Pharmaceutical (Pvt) Ltd.
Ofen Libra Pharmaceuticals (Pvt) Ltd
Onyfen Onyx Pharmaceutical
Ottofen Eros Pharmaceuticals
Paincare Care & Cure
Panil Delux Chemical Industries
Pedifen Ferozsons Laboratoies Ltd.
Pedifen Ferozsons Laboratoies Ltd.
Phine Mac & Rans Pharmaceuticals (Pvt) Ltd
Pironec Atlantic Pharmaceuticals (Pvt) Ltd.
Pironec Plus Atlantic Pharmaceuticals (Pvt) Ltd.
Prexol Asian Agencies
Proflam Polyfine Chempharma (Pvt) Ltd.
Prosta Global Pharmaceuticals
Pyrofen Sharex Laboratories (Pvt.) Ltd.
Pyrofen Sharex Laboratories (Pvt.) Ltd.
Q-Fen Hassan Pharmaceuticals (Pvt) Ltd.
Remofen Syntex Pharmaceuticals
Rhunor Wahabsons Pharma
Ruberin W.Woodward Pakistan (Pvt) Ltd.
Rumafen Atco Laboratories Limited
Rumatofen Karachi Pharmaceutical Laboratory
Rumin Ankaz Pharmex (Pvt) Ltd.
Semorfen Semos Pharmaceuticals (Pvt) Ltd.
Stabru Standard Drug Co.
Synofen Synchro Pharmaceuticals
Tabalon Sanofi Aventis (Pakistan) Ltd.
Werridal Werrick Pharmaceuticals
Wilfen Wilshire Laboratories (Pvt) Ltd.
Xiben Pacific Pharmaceuticals Ltd.
Zayfen Zaynoon Pharmaceuticals
Zefen Xenon Pharmaceuticals (Pvt) Ltd.
Zefrin Fozan Pharmaceuticals Industriers (Pvt) Ltd
Zintafen Zinta Pharmaceuticals Industries
Zufen Zanctok Pharmaceuticals

 

Ibuprofen Suspension 200 mg/5ml

Brufen Abbott Laboratories (Pakistan) Limited.

 

Ibuprofen Oral Solution 100 Mg

Ibunol Miracle Pharmaceuticals(Pvt) Ltd

 

Ibuprofen Cream 10 % W/W

Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Artijesic Medisearch Pharmacal(Pvt) Ltd
Brufen Abbott Laboratories (Pakistan) Limited.
Ibugray Gray`S Pharmaceuticals
Karbufen Genix Pharma (Pvt) Ltd

Ibuprofen Patches: 30 mg

Kefentech Matrix Pharma

 

Ibuprofen Gel 10 % W/W

Rumafen Atco Laboratories Limited

 

Ibuprofen 200 mg Tablets

Actifen Glaxosmithkline
Al-Fen Alina Combine Pharmaceuticals (Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Amrofen Amros Pharmaceuticals.
Anglofen Euro Pharma International
Arufen Progressive Laboratories
B-Fen Helicon Pharmaceutek Pakistan (Pvt) Ltd.
Baprofen Batala Pharmaceuticals.
Baprofen Batala Pharmaceuticals.
Bludol Standpharm Pakistan (Pvt) Ltd.
Boschofen Bosch Pharmaceuticals (Pvt) Ltd.
Bravofen Mega Pharmaceuticals (Pvt) Ltd
Brufen Abbott Laboratories (Pakistan) Limited.
Brufen Abbott Laboratories (Pakistan) Limited.
Bumex Multinational Buisness Link
Dolocol Semos Pharmaceuticals (Pvt) Ltd.
Dorafen Dosaco Laboratories
Eurofen Euro Pharma International
Everfen Evergreen Pharmaceuticals Pvt Limited
Fenober Trigon Pharmaceuticals Pakistan (Pvt) Ltd.
Ferrofen Ferro Pharmaceutical Laboratories
Ferrofen Ferro Pharmaceutical Laboratories
Fufen Flow Pharmaceuticals (Pvt) Ltd.
Fufen Flow Pharmaceuticals (Pvt) Ltd.
Hibtol Don Valley Pharmaceuticals (Pvt) Ltd.
Hifen Helix Pharma (Private) Limited
Hizofen Hizat Pharmaceutical Industries (Pvt) Ltd.
Ibowin Jinnah Pharmaceuticals
Ibu Unexo Labs (Pvt) Ltd.
Ibu Unexo Labs (Pvt) Ltd.
Ibufin Medicaids Pakistan (Pvt) Ltd.
Ibufin Medicaids Pakistan (Pvt) Ltd.
Ibulexin Lexicon Pharmaceuticals (Pvt) Ltd.
Ibumid P.D.H. Pharmaceuticals (Pvt) Ltd.
Ibumid P.D.H. Pharmaceuticals (Pvt) Ltd.
Ibuprofen Siza International (Pvt) Ltd.
Ibuprofen Munawar Pharma (Pvt) Ltd.
Ibuprofen Siza International (Pvt) Ltd.
Ibuprofen Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Ibuprofen Unipharma (Pvt) Ltd.
Ibuprofen Unipharma (Pvt) Ltd.
Ibuprofen Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Ibuprofen Geofman Pharmaceuticals
Ibuprofen Unison Chemical Works
Ibuprofen Geofman Pharmaceuticals
Iburin Hamaz Pharmaceutical (Pvt) Ltd.
Iburin Hamaz Pharmaceutical (Pvt) Ltd.
Ibuser Star Laboratories (Pvt) Ltd.
Ifen Adamjee Pharmaceuticals (Pvt) Ltd.
Igrafen Specific Research Laboratories
Inflam Spencer Pharma
Iodofen Ideal Pharmaceutical Industries
Iodofen Ideal Pharmaceutical Industries
Jaefen Irza Pharma (Pvt) Ltd.
Jaefen Irza Pharma (Pvt) Ltd.
Kayfen Karachi Chemical Industries
Medibrrufen Mediate Pharmaceuticals (Pvt) Ltd
Medibru Medera Pharmaceuticals (Pvt) Ltd.
Megafen Albro Pharma
Megafen Albro Pharma
Mufen Macquins International
Nenfen Nenza Pharmaceuticals (Pvt) Limited
Neo-Butinal Schazoo Zaka
Neo-Butinal Schazoo Zaka
Novofen Krka-Pak Pharmaceutical & Chemical Works
Novofen Krka-Pak Pharmaceutical & Chemical Works
Novofen Krka-Pak Pharmaceutical & Chemical Works
Ocefen Safe Pharmaceutical (Pvt) Ltd.
Ocefen Safe Pharmaceutical (Pvt) Ltd.
Ofcin Obsons Pharmaceuticals
Ottofen Eros Pharmaceuticals
Pango Efroze Chemical Industries (Pvt) Ltd.
Pango Efroze Chemical Industries (Pvt) Ltd.
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Profen Ferozsons Laboratoies Ltd.
Profen Ferozsons Laboratoies Ltd.
Promin Pharmawise Labs. (Pvt) Ltd.
Promin Pharmawise Labs. (Pvt) Ltd.
Prufo Valor Pharmaceuticals
Pyrofen Sharex Laboratories (Pvt.) Ltd.
Regofen Regent Laboratories Ltd.
Resfen Rasco Pharma
Resfen Rasco Pharma
Rumat Ferroza International Pharmaceuticals (Pvt) Ltd.
Rumatofen Karachi Pharmaceutical Laboratory
Rumatofen Karachi Pharmaceutical Laboratory
Rumin Ankaz Pharmex (Pvt) Ltd.
Semorfen Semos Pharmaceuticals (Pvt) Ltd.
Suprofen Kohs Pharmaceuticals
Tagafin Tagma Pharma (Pvt) Ltd.
True-Fen Mass Pharma (Private) Limited
True-Fen Mass Pharma (Private) Limited
Uniprofen Unison Chemical Works
Vee Bufen Venus Pharma
Wilfen Wilshire Laboratories (Pvt) Ltd.
Wilfen Wilshire Laboratories (Pvt) Ltd.
Zufen Zanctok Pharmaceuticals

 

Ibuprofen 400 mg Tablets

Actifen Glaxosmithkline
Aksofen Akson Pharmaceuticals (Pvt) Ltd.
Al-Fen Alina Combine Pharmaceuticals (Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Ambrofen Jawa Pharmaceuticals(Pvt) Ltd.
Amrofen Amros Pharmaceuticals.
Anglofen Euro Pharma International
Apro Tablet Ambrosia Pharmaceuticals
Azofin Alkemy Pharmaceutical Laboratories (Private) Ltd.
B-Fen Helicon Pharmaceutek Pakistan (Pvt) Ltd.
Baprofen Batala Pharmaceuticals.
Baprofen Batala Pharmaceuticals.
Bludol Standpharm Pakistan (Pvt) Ltd.
Boschofen Bosch Pharmaceuticals (Pvt) Ltd.
Bravofen Mega Pharmaceuticals (Pvt) Ltd
Brufedin Ardin Pharmaceuticals
Brufen Abbott Laboratories (Pakistan) Limited.
Brufen Abbott Laboratories (Pakistan) Limited.
Cayprof Caylex Pharmaceuticals (Pvt) Ltd.
Deltafen Delta Pharma (Pvt) Ltd.
Dolocol Forte Semos Pharmaceuticals (Pvt) Ltd.
Dolofen Agp (Private) Ltd.
Dorafen Dosaco Laboratories
Eprofen Epoch Pharmaceutical
Eprofen Epoch Pharmaceutical
Eurofen Euro Pharma International
Everfen Evergreen Pharmaceuticals Pvt Limited
Fenflex Pakheim Internanational Pharma
Ferrofen Ferro Pharmaceutical Laboratories
Ferrofen Ferro Pharmaceutical Laboratories
Fufen Flow Pharmaceuticals (Pvt) Ltd.
Fufen Flow Pharmaceuticals (Pvt) Ltd.
Hebofen Heal Pharmaceuticals Pvt Ltd
Hifen Helix Pharma (Private) Limited
Hizofen Hizat Pharmaceutical Industries (Pvt) Ltd.
Ibowin Jinnah Pharmaceuticals
Ibu Unexo Labs (Pvt) Ltd.
Ibu Unexo Labs (Pvt) Ltd.
Ibucare Adcare Pharma
Ibucare Aims Traders
Ibufin Medicaids Pakistan (Pvt) Ltd.
Ibufin Medicaids Pakistan (Pvt) Ltd.
Ibugen Genera Pharmaceuticals
Ibugen Genera Pharmaceuticals
Ibugen Genera Pharmaceuticals
Ibugray Gray`S Pharmaceuticals
Ibumid P.D.H. Pharmaceuticals (Pvt) Ltd.
Ibumid P.D.H. Pharmaceuticals (Pvt) Ltd.
Ibuprofen Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Ibuprofen Munawar Pharma (Pvt) Ltd.
Ibuprofen Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Ibuprofen Siza International (Pvt) Ltd.
Ibuprofen Geofman Pharmaceuticals
Ibupulse Pulse Pharmaceuticals
Iburin Hamaz Pharmaceutical (Pvt) Ltd.
Iburin Hamaz Pharmaceutical (Pvt) Ltd.
Ibuser Star Laboratories (Pvt) Ltd.
Ifen Adamjee Pharmaceuticals (Pvt) Ltd.
Inflam Spencer Pharma
Iodofen Ideal Pharmaceutical Industries
Jaefen Irza Pharma (Pvt) Ltd.
Jaefen Irza Pharma (Pvt) Ltd.
Kanflam Medisure Laboratories Pakistan (Pvt.) Ltd.
Kayfen Karachi Chemical Industries
Mb-Fen Multinational Buisness Link
Medibru Medera Pharmaceuticals (Pvt) Ltd.
Medibrufen Mediate Pharmaceuticals (Pvt) Ltd
Megafen Albro Pharma
Mufen Macquins International
Nenfen Nenza Pharmaceuticals (Pvt) Limited
Neo-Butinal Schazoo Zaka
Neo-Butinal Schazoo Zaka
Novofen Krka-Pak Pharmaceutical & Chemical Works
Novofen Krka-Pak Pharmaceutical & Chemical Works
Novofen Krka-Pak Pharmaceutical & Chemical Works
Ocefen Safe Pharmaceutical (Pvt) Ltd.
Ocefen Safe Pharmaceutical (Pvt) Ltd.
Ofen Libra Pharmaceuticals (Pvt) Ltd
Ottofen Eros Pharmaceuticals
Pabrofen Drug Pharm (Pvt) Ltd.
Pango Efroze Chemical Industries (Pvt) Ltd.
Pango Efroze Chemical Industries (Pvt) Ltd.
Panil Delux Chemical Industries
Pesudomol Fort Ambrosia Pharmaceuticals
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Pharfen Pharmacare Laboratories (Pvt) Ltd.
Profen Ferozsons Laboratoies Ltd.
Profen Ferozsons Laboratoies Ltd.
Promin Pharmawise Labs. (Pvt) Ltd.
Promin Pharmawise Labs. (Pvt) Ltd.
Propen Global Pharmaceuticals
Prufo Valor Pharmaceuticals
Pyrofen Sharex Laboratories (Pvt.) Ltd.
Rapifen Pharmix Laboratories (Private) Limited.
Regofen Regent Laboratories Ltd.
Remofen Syntex Pharmaceuticals
Remofen Syntex Pharmaceuticals
Resfen Rasco Pharma
Resfen Rasco Pharma
Rexaprofen S.J. & G. Fazul Ellahie (Pvt) Ltd.
Rumat Ferroza International Pharmaceuticals (Pvt) Ltd.
Rumatofen Karachi Pharmaceutical Laboratory
Rumatofen Karachi Pharmaceutical Laboratory
Rumin Ankaz Pharmex (Pvt) Ltd.
Semorfen Semos Pharmaceuticals (Pvt) Ltd.
Semorfen Semos Pharmaceuticals (Pvt) Ltd.
Suprofen Kohs Pharmaceuticals
Tagafin Tagma Pharma (Pvt) Ltd.
Tesco Nimrall Laboratories
Tesco Nimrall Laboratories
True-Fen Mass Pharma (Private) Limited
True-Fen Mass Pharma (Private) Limited
Unifen Tg Pharma
Uniprofin Unison Chemical Works
Varinac Genome Pharmaceuticals (Pvt) Ltd
Vee Bufen Venus Pharma
Vee Bufen Venus Pharma
Wefen Webros Pharmaceuticals
Wilfen Wilshire Laboratories (Pvt) Ltd.
Wilfen Wilshire Laboratories (Pvt) Ltd.
Xiben Pacific Pharmaceuticals Ltd.
Zefen Xenon Pharmaceuticals (Pvt) Ltd.
Zefen Xenon Pharmaceuticals (Pvt) Ltd.
Zintafen Zinta Pharmaceuticals Industries
Zufen Zanctok Pharmaceuticals

 

Ibuprofen 600 mg Tablets

Actifen Glaxosmithkline
Brufen Abbott Laboratories (Pakistan) Limited.
Ibu Unexo Labs (Pvt) Ltd.
Ibu Unexo Labs (Pvt) Ltd.
Ibu-Slow Europak Pharma (Pvt) Ltd
Ibucil Mediceena Pharma (Pvt) Ltd.
Ifen Adamjee Pharmaceuticals (Pvt) Ltd.
Inflam Spencer Pharma
Panil Delux Chemical Industries
Profen Ferozsons Laboratoies Ltd.
Profen Ferozsons Laboratoies Ltd.
Prosta Global Pharmaceuticals
Prufo Valor Pharmaceuticals

 

Ibuprofen SR 800 mg Tablets

Brufen Retard Abbott Laboratories (Pakistan) Limited.

 

Ibuprofen 200 mg Capsules

Ibuquik Zafa Pharmaceutical Laboratories (Pvt) Ltd.
Ibusoft Zafa Pharmaceutical Laboratories (Pvt) Ltd.

 

Ibuprofen 400 mg Capsules

Ibuquik Zafa Pharmaceutical Laboratories (Pvt) Ltd.

 

Ibuprofen 100 mg Powder

Brucam Hoover Pharmaceuticals (Pvt) Ltd

  [/bg_collapse]

Comments

NO Comments Found